Bausch + Lomb Co. (NYSE:BLCO) Receives Consensus Recommendation of "Hold" from Brokerages

Bausch + Lomb Co. (NYSE:BLCO - Get Free Report) has received a consensus rating of "Hold" from the thirteen analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $20.25.

A number of research analysts have issued reports on the stock. Bank of America reissued an "underperform" rating and set a $18.00 price objective on shares of Bausch + Lomb in a research report on Thursday, December 12th. Morgan Stanley cut shares of Bausch + Lomb from an "overweight" rating to an "equal weight" rating and set a $19.00 price target on the stock. in a research report on Monday, December 2nd. Stifel Nicolaus lowered their price objective on shares of Bausch + Lomb from $19.00 to $18.00 and set a "hold" rating for the company in a report on Wednesday. Needham & Company LLC reiterated a "hold" rating on shares of Bausch + Lomb in a report on Thursday, October 31st. Finally, Wells Fargo & Company lowered their target price on Bausch + Lomb from $26.00 to $24.00 and set an "overweight" rating for the company in a research note on Thursday, January 16th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BLCO. Dimensional Fund Advisors LP increased its holdings in Bausch + Lomb by 53.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 67,690 shares of the company's stock worth $984,000 after buying an additional 23,714 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Bausch + Lomb in the second quarter worth approximately $1,911,000. Cubist Systematic Strategies LLC purchased a new position in shares of Bausch + Lomb during the second quarter valued at approximately $580,000. Squarepoint Ops LLC bought a new position in Bausch + Lomb during the second quarter valued at approximately $173,000. Finally, Renaissance Capital LLC boosted its holdings in Bausch + Lomb by 20.0% in the third quarter. Renaissance Capital LLC now owns 43,560 shares of the company's stock worth $840,000 after purchasing an additional 7,274 shares during the last quarter. Institutional investors own 11.07% of the company's stock.

Bausch + Lomb Trading Down 1.4 %

Shares of NYSE BLCO traded down $0.25 during trading hours on Thursday, hitting $17.63. The company's stock had a trading volume of 358,261 shares, compared to its average volume of 572,351. The business has a 50-day simple moving average of $18.38 and a 200-day simple moving average of $18.13. The stock has a market cap of $6.21 billion, a price-to-earnings ratio of -16.79, a P/E/G ratio of 2.17 and a beta of 0.47. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57. Bausch + Lomb has a 12 month low of $13.16 and a 12 month high of $21.69.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of $0.16 by $0.01. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period last year, the company earned $0.22 EPS. The business's quarterly revenue was up 18.8% compared to the same quarter last year. On average, analysts anticipate that Bausch + Lomb will post 0.6 earnings per share for the current fiscal year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.